Researchers grow immune cells with more targeted cancer-fighting abilities

Researchers at the University of California, Berkeley, have made a groundbreaking discovery that could revolutionize the way we treat diseases using immune cells. Their findings, published in the journal Advanced Materials, suggest that the stiffening of lymph nodes may play a crucial role in activating our immune system to fight serious infections or threats. This new understanding could lead to a revolutionary method for manufacturing immune cells that are more effective at targeting cancer cells while minimizing side effects.

Lymph nodes are often referred to as the command centers of the immune system, and they frequently swell and stiffen when the body is fighting an infection. Researchers led by Derfogail Delcassian, an assistant professor of bioengineering at UC Berkeley, investigated how immune cells respond to different mechanical environments. To do this, they exposed T cells, also known as lymphocytes, to hydrogels with varying levels of stiffness, which mimicked the surface of a natural lymph node.

The study revealed that immune cells activated on stiffer materials were more effective at killing target cancer cells. However, cells activated on softer materials demonstrated greater precision in their targeting, hitting only the intended cells and causing fewer off-target side effects. Delcassian explained that the stiffening of lymph nodes is a natural way for the body to activate immune cells to respond aggressively to serious infections or threats.

Currently, T cell and CAR-T cell therapies are manufactured using a "stiff activation" approach. While this method can be highly effective for treating cancer, it can sometimes lead to excessive aggression, causing the immune cells to attack off-target cells. This can result in hyperinflammation and other adverse side effects for patients. Moreover, super-aggressive T cells may worsen autoimmune diseases, which are conditions where the immune system mistakenly attacks the body's own cells.

The Berkeley research team's findings offer a potential solution to these challenges. By understanding how mechanical cues influence immune cell activation, they can now develop a "soft activation" approach that allows for more controlled levels of immune cell activation. This means that T cell and CAR-T cell therapies can be tailored to suit a wider range of diseases, from cancer to autoimmune conditions, while reducing the risk of off-target side effects.

Delcassian emphasized the potential of this new method, stating, "Using this system, we can now manufacture immune cells with more controlled activation levels. This will make T cell and CAR-T cell therapies suitable for a wider range of diseases and may limit off-target side effects in patients."

This breakthrough in understanding the role of mechanical cues in immune cell activation could pave the way for more targeted and effective therapies. By harnessing the natural mechanisms of the immune system, researchers are poised to develop treatments that are not only more effective but also safer for patients. As the field of immunotherapy continues to evolve, this innovative approach to immune cell manufacturing holds great promise for improving outcomes in a variety of medical conditions.